Gyre Therapeutics
GYRE
34 hedge funds and large institutions have $2.63M invested in Gyre Therapeutics in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 7 closing their positions.
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
1.16% less ownership
Funds ownership: 3.28% → 2.11% (-1.2%)
3% less funds holding
Funds holding: 35 → 34 (-1)
32% less capital invested
Capital invested by funds: $3.9M → $2.63M (-$1.26M)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$136K |
| 2 |
Renaissance Technologies
New York
|
+$46.6K |
| 3 |
BSW
Buckingham Strategic Wealth
Clayton,
Missouri
|
+$23.5K |
| 4 |
Jane Street
New York
|
+$17K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$14.2K |
Top Sellers
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.15M |
| 2 |
Millennium Management
New York
|
-$381K |
| 3 |
RC
RBF Capital
San Francisco,
California
|
-$51K |
| 4 |
Goldman Sachs
New York
|
-$46K |
| 5 |
VF
Virtu Financial
New York
|
-$31.5K |
GYRE Hedge Fund Activity: Q4 2022 in Review
34 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2022, worth a combined $2.63M — down 32% from $3.9M a quarter earlier.
Fund positioning in GYRE was balanced in Q4 2022: 7 funds opened new positions, 7 closed out, 8 added to existing stakes and 12 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $136K. The largest seller was Nantahala Capital Management, cutting an estimated $1.15M.
- 34 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2022, down from 35 in Q3 2022.
- Funds reported $2.63M of Gyre Therapeutics stock for Q4 2022, down 32% quarter-over-quarter.
- 7 funds opened new Gyre Therapeutics positions in Q4 2022 and 7 closed out, a net change of 0 holders.
- The largest Gyre Therapeutics buyer in Q4 2022 was Citadel Advisors, an estimated $136K added.
- The largest Gyre Therapeutics seller in Q4 2022 was Nantahala Capital Management, an estimated $1.15M sold.
Based on aggregated 13F filings for Q4 2022.